The beneficial role of SGLT2 treatment among patients with heart failure (HF) is already confirmed and is demonstrated by a significant decrease in the hospitalizations rate due to HF and CV mortality (McMurray et al., 2019; Gager et al., 2021; Packer et al., 2021). Here, SLC5A2 is linked to hydrops fetalis.